JACKSONVILLE, Fla.,
May 23, 2018 /PRNewswire/
-- TapImmune Inc. (NASDAQ: TPIV), a clinical-stage
immuno-oncology company, announced today that Peter Hoang, President and CEO, will host a
video webinar and slide presentation to discuss the details of the
proposed merger with Marker Therapeutics, Inc., on Thursday, May 24, 2018, at 4:05 p.m. ET. The webinar will be followed by a
live Q&A session. To view the webinar, please visit
https://www.redchip.com/events/25/tapimmune-webinar, or the events
section of TapImmune's website at
http://www.tapimmune.com/events.
Mr. Hoang will discuss the details of the merger, highlighting
in a slide presentation how the transaction represents the next
major leap forward in cell therapy for cancer and how the
opportunity could significantly disrupt the CAR-T and TCR
field.
About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel
immunotherapies for cancer, with multiple Phase 2 and Phase
1b/2 clinical studies currently
ongoing for the treatment of ovarian and breast cancer. The
Company's peptide or nucleic acid-based immunotherapeutic products
comprise multiple naturally processed epitopes (NPEs) that are
designed to comprehensively stimulate a patient's killer T cells
and helper T cells, and to restore or further augment antigen
presentation using proprietary nucleic acid-based expression
systems. This unique approach can produce off-the-shelf T cell
vaccine candidates that elicit a broad-based T cell response and
can be used without respect to HLA type. The Company's technologies
may be used as stand-alone medications or in combination with other
treatment modalities. TapImmune has announced a proposed merger
with Marker Therapeutics, Inc., a privately-held clinical-stage
developer of a transformative, non-genetically engineered,
multi-antigen T cell therapy platform, which will add a significant
portfolio of clinical-stage cell therapies to create a leading
immuno-oncology pipeline.
For additional information, please visit:
https://tapimmune.com/.
To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/.
Follow us on Twitter @Tapimmune_Inc, or follow us on
Facebook.
For answers to frequently asked questions, please visit our FAQs
page:
https://tapimmune.com/investors/frequently-asked-questions/.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's
expectations, plans, business outlook or future performance, and
any other statements concerning assumptions made or expectations as
to any future events, conditions, performance or other matters, are
"forward-looking statements". Forward-looking statements are by
their nature subject to risks, uncertainties and other factors
which could cause actual results to differ materially from those
stored in such statements. Such risks, uncertainties and factors
include, but are not limited to the results of the Phase 2 clinical
trials, the ability to obtain regulatory approval of TPIV200, the
Company's ability to raise future financing for continued
development and the ability to successfully commercialize TPIV200
as well as the risks and uncertainties set forth in the Company's
most recent Form 10-K, 10-Q and other SEC filings which are
available through EDGAR at www.sec.gov. The Company assumes no
obligation to update the forward-looking statements.
View original content with
multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-host-investor-webinar-on-thursday-may-24th-to-discuss-proposed-merger-with-marker-therapeutics-and-its-transformational-t-cell-therapy-platform-300653196.html
SOURCE TapImmune Inc.
